Endovastec(SH:688016) Sou Hu Cai Jing·2025-12-22 12:21Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance in its recent quarterly report, with revenue growth but a decline in net profit [2] - As of December 22, 2025, Xinmai Medical's stock closed at 92.76 yuan, with a slight decrease of 0.04% and a trading volume of 7417 lots, amounting to a total transaction value of 68.92 million yuan [1] - In the recent funding flow data, there was a net outflow of 0.96 thousand yuan from main funds, while retail investors experienced a net outflow of 325.15 thousand yuan, indicating a shift in investor sentiment [1] Group 2 - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The third quarter of 2025 saw a significant increase in revenue, reaching 300 million yuan, which is a 64.68% year-on-year growth, although the net profit for the quarter still declined by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85% and a gross profit margin of 70.4%, indicating a strong financial position despite the profit decline [2]